1. World Health Organization. WHO World Health Report 2002: reducing risks, promoting healthy life. p. 49-97 [Internet]. Geneva: World Health Organization;2003. cited 2013 Aug 17. Available from:
http://www.who.int/whr/2002/index.html.
2. Rohn TA, Bachmann MF. Vaccines against non-communicable diseases. Curr Opin Immunol. 2010; 22:391–396.
Article
4. Eckel RH, Kahn SE, Ferrannini E, et al. Obesity and type 2 diabetes: what can be unified and what needs to be individualized? J Clin Endocrinol Metab. 2011; 96:1654–1663.
Article
5. Schuster DP. Obesity and the development of type 2 diabetes: the effects of fatty tissue inflammation. Diabetes Metab Syndr Obes. 2010; 3:253–262.
Article
6. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus: present and future perspectives. Nat Rev Endocrinol. 2012; 8:228–236.
Article
7. Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA. 2005; 293:43–53.
Article
8. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007; 369:71–77.
Article
9. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007; 357:753–761.
Article
10. Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007; 357:741–752.
Article
11. Melnikova I, Wages D. Anti-obesity therapies. Nat Rev Drug Discov. 2006; 5:369–370.
Article
12. Ariyasu H, Takaya K, Tagami T, et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab. 2001; 86:4753–4758.
Article
13. Inui A, Asakawa A, Bowers CY, et al. Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ. FASEB J. 2004; 18:439–456.
Article
14. Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev. 2007; 8:21–34.
Article
15. St-Pierre DH, Karelis AD, Cianflone K, et al. Relationship between ghrelin and energy expenditure in healthy young women. J Clin Endocrinol Metab. 2004; 89:5993–5997.
Article
16. Zorrilla EP, Iwasaki S, Moss JA, et al. Vaccination against weight gain. Proc Natl Acad Sci U S A. 2006; 103:13226–13231.
Article
17. Wilding JP. Neuropeptides and appetite control. Diabet Med. 2002; 19:619–627.
Article
18. Rojas JM, Stafford JM, Saadat S, Printz RL, Beck-Sickinger AG, Niswender KD. Central nervous system neuropeptide Y signaling via the Y1 receptor partially dissociates feeding behavior from lipoprotein metabolism in lean rats. Am J Physiol Endocrinol Metab. 2012; 303:E1479–E1488.
Article
20. Johnson JE, Chiu W. Structures of virus and virus-like particles. Curr Opin Struct Biol. 2000; 10:229–235.
Article
21. Pumpens P, Grens E. Hepatitis B core particles as a universal display model: a structure-function basis for development. FEBS Lett. 1999; 442:1–6.
Article
22. Kozlovska TM, Cielens I, Dreilinna D, et al. Recombinant RNA phage Q beta capsid particles synthesized and self-assembled in Escherichia coli. Gene. 1993; 137:133–137.
Article
23. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004; 303:1526–1529.
Article
24. Bessa J, Jegerlehner A, Hinton HJ, et al. Alveolar macrophages and lung dendritic cells sense RNA and drive mucosal IgA responses. J Immunol. 2009; 183:3788–3799.
Article
25. Hou B, Saudan P, Ott G, et al. Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. Immunity. 2011; 34:375–384.
Article
26. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006; 444:840–846.
Article
27. Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen JH, Dinarello CA, Svenson M. Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science. 1986; 232:1545–1547.
Article
28. Dinarello CA, Donath MY, Mandrup-Poulsen T. Role of IL-1beta in type 2 diabetes. Curr Opin Endocrinol Diabetes Obes. 2010; 17:314–321.
29. Bachmann MF, Jennings GT. Therapeutic vaccines for chronic diseases: successes and technical challenges. Philos Trans R Soc Lond B Biol Sci. 2011; 366:2815–2822.
Article
30. Spohn G, Keller I, Beck M, Grest P, Jennings GT, Bachmann MF. Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur J Immunol. 2008; 38:877–887.
Article
31. Marti A, Marcos A, Martinez JA. Obesity and immune function relationships. Obes Rev. 2001; 2:131–140.
Article
32. Kim YH, Kim JK, Kim DJ, et al. Diet-induced obesity dramatically reduces the efficacy of a 2009 pandemic H1N1 vaccine in a mouse model. J Infect Dis. 2012; 205:244–251.
Article
33. Weber DJ, Rutala WA, Samsa GP, Santimaw JE, Lemon SM. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA. 1985; 254:3187–3189.
Article
34. Young MD, Gooch WM 3rd, Zuckerman AJ, Du W, Dickson B, Maddrey WC. Comparison of a triple antigen and a single antigen recombinant vaccine for adult hepatitis B vaccination. J Med Virol. 2001; 64:290–298.
Article
35. Claycombe K, King LE, Fraker PJ. A role for leptin in sustaining lymphopoiesis and myelopoiesis. Proc Natl Acad Sci U S A. 2008; 105:2017–2021.
Article
36. Dhurandhar NV, Israel BA, Kolesar JM, Mayhew GF, Cook ME, Atkinson RL. Increased adiposity in animals due to a human virus. Int J Obes Relat Metab Disord. 2000; 24:989–996.
Article
37. Dhurandhar NV, Israel BA, Kolesar JM, Mayhew G, Cook ME, Atkinson RL. Transmissibility of adenovirus-induced adiposity in a chicken model. Int J Obes Relat Metab Disord. 2001; 25:990–996.
Article
38. Dhurandhar NV, Whigham LD, Abbott DH, et al. Human adenovirus Ad-36 promotes weight gain in male rhesus and marmoset monkeys. J Nutr. 2002; 132:3155–3160.
Article
39. van Ginneken V, Sitnyakowsky L, Jeffery JE. "Infectobesity: viral infections (especially with human adenovirus-36: Ad-36) may be a cause of obesity. Med Hypotheses. 2009; 72:383–388.
Article
40. Atkinson RL, Dhurandhar NV, Allison DB, et al. Human adenovirus-36 is associated with increased body weight and paradoxical reduction of serum lipids. Int J Obes (Lond). 2005; 29:281–286.
Article
41. Na HN, Hong YM, Kim J, Kim HK, Jo I, Nam JH. Association between human adenovirus-36 and lipid disorders in Korean schoolchildren. Int J Obes (Lond). 2010; 34:89–93.
Article
42. Atkinson RL, Lee I, Shin HJ, He J. Human adenovirus-36 antibody status is associated with obesity in children. Int J Pediatr Obes. 2010; 5:157–160.
Article
43. Trovato GM, Castro A, Tonzuso A, et al. Human obesity relationship with Ad36 adenovirus and insulin resistance. Int J Obes (Lond). 2009; 33:1402–1409.
Article
44. Gabbert C, Donohue M, Arnold J, Schwimmer JB. Adenovirus 36 and obesity in children and adolescents. Pediatrics. 2010; 126:721–726.
Article
45. Pasarica M, Loiler S, Dhurandhar NV. Acute effect of infection by adipogenic human adenovirus Ad36. Arch Virol. 2008; 153:2097–2102.
Article